Lung cancer treatment is evolving — and immunotherapy is changing who benefits, how, and why. In this expert session, Dr. Madhura Ambekar, Consultant Medical & Hemato-Oncologist, explains how immunotherapy is reshaping lung cancer care by activating the body’s own immune system to fight disease more effectively. The conversation focuses on identifying the right patients, understanding biomarkers like PD-L1, and clarifying why immunotherapy delivers better outcomes and quality of life for selecte

If one immunotherapy doesn’t work, will another one help? 🔍 Dr. John Hunting explains why most immunotherapies target the same pathway (the same “flag”), and why switching drugs often won’t create a different response—especially if the cancer isn’t using that pathway to begin with. Cancer can be sneaky, using many different ways to hide from the immune system. That’s why not every tumor responds to PD-1/PD-L1 treatments. 📺 Watch the full presentation for more expert SCLC updates: https://youtu

Immune Checkpoint Inhibitors

PD-L1, PD1,TMB and Lung Cancer

Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder Cancer | OncLive

PD-L1 Biomarker Testing | OncLive

Value of PD-L1 Biomarker in NPC | OncLive

Dr. Powles on PD-L1 as a Biomarker in RCC | OncLive